Ads
related to: acute myeloid leukemia peripheral smear- Targeted Treatment
Learn More About A Treatment Option
For Acute Myeloid Leukemia (AML).
- Dosing & Side Effect Info
Get Dosing, Storage Information &
Possible Side Effect Information
- Clinical Study Results
Review Results & Learn The Benefits
Of A Targeted Treatment Option.
- Official Patient Website
AML Treatment Option
Combination Therapy for AML
- Prescribing Information
Full Medication Guide & Important
Safety Information Available
- AML & IDH Mutations
Read About Acute Myeloid Leukemia,
Relapsed & Refractory Diagnoses
- Targeted Treatment
Search results
Results From The WOW.Com Content Network
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. [1] Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. [1]
Acute myeloid leukemia is a very heterogeneous disease, composed of a variety of translocations and mutations. However, one tenth of all acute myeloid leukemia cases diagnosed have the AML1-ETO fusion oncoprotein due to the t(8;21) translocation. AML1 or RUNX1 is a DNA-binding transcription factor located at the 21q22.
Testing available to diagnosis AML includes a complete blood count which is characterized by blood that is taken from the vein in the arm to test for leukemia, a peripheral blood smear and a bone marrow test. During a peripheral blood smear, a sample of blood is checked for blast cells, white blood cell count and changes in shape of blood cells ...
Conventionally, a leukocytosis exceeding 50,000 WBC/mm 3 with a significant increase in early neutrophil precursors is referred to as a leukemoid reaction. [2] The peripheral blood smear may show myelocytes, metamyelocytes, promyelocytes, and rarely myeloblasts; however, there is a mixture of early mature neutrophil precursors, in contrast to the immature forms typically seen in acute leukemia.
Acute promyelocytic leukemia is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARA) gene on chromosome 17. [3] In 95% of cases of APL, the RARA gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (PML) on chromosome 15, a translocation denoted as t(15;17)(q22;q21). [3]
The best way to diagnose dysplasia is by morphology and special stains used on the bone marrow aspirate and peripheral blood smear. Dysplasia in the myeloid series is defined by: Dysplasia in the myeloid series is defined by:
Ads
related to: acute myeloid leukemia peripheral smear